Clinical trials of the Epivakkorone vaccine among people over 65 have been completed in Russia. The head of Rospotrebnadzor Anna Popova told about this on the air of the Russia-1 TV channel.
She noted that in the near future, permission will be obtained to vaccinate this category of the population.
“We are waiting for this literally from day to day,” Popova clarified.
Earlier in the center “Vector” reported that the older volunteers who participated in the tests of the drug “Epivakkorona”, the immune response amounted to 94%.
As a reminder, the vaccine of the Vector Center received a registration certificate in October 2020. In November, the Ministry of Health authorized the start of post-registration studies of the drug “Epivakkorona” on volunteers over 60 years old.
Read more about the differences between Russian vaccines against COVID-19. in the material “AiF”.